APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense Oligonucleotide Therapies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antisense Oligonucleotide Therapies Market Outlook and Growth Opportunities 2026

31 December 2025198 pages

Choose your research edition.

Industry ResearchAntisense Oligonucleotide Therapies Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense Oligonucleotide Therapies Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Antisense Oligonucleotide Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense Oligonucleotide Therapies Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense Oligonucleotide Therapies Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Antisense Oligonucleotide Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antisense Oligonucleotide Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antisense Oligonucleotide Therapies market include Sarepta Therapeutics, Nippon Shinyaku and Ionis Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antisense Oligonucleotide Therapies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antisense Oligonucleotide Therapies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antisense Oligonucleotide Therapies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antisense Oligonucleotide Therapies market.

Antisense Oligonucleotide Therapies Segment by Company

Sarepta Therapeutics

Nippon Shinyaku

Ionis Pharmaceuticals

Antisense Oligonucleotide Therapies Segment by Type

Without GalNAc-conjugated

With GalNAc-conjugated

Antisense Oligonucleotide Therapies Segment by Application

Cancer

Cardiovascular Diseases

Genetic Disease

Other

Antisense Oligonucleotide Therapies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antisense Oligonucleotide Therapies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antisense Oligonucleotide Therapies key companies, revenue, market share, and recent developments.

3. To split the Antisense Oligonucleotide Therapies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antisense Oligonucleotide Therapies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antisense Oligonucleotide Therapies significant trends, drivers, influence factors in global and regions.

6. To analyze Antisense Oligonucleotide Therapies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense Oligonucleotide Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense Oligonucleotide Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense Oligonucleotide Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antisense Oligonucleotide Therapies industry.

Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antisense Oligonucleotide Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antisense Oligonucleotide Therapies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antisense Oligonucleotide Therapies Industry Trends Table 2. Antisense Oligonucleotide Therapies Industry Drivers Table 3. Antisense Oligonucleotide Therapies Industry Opportunities and Challenges Table 4. Antisense Oligonucleotide Therapies Industry Restraints Table 5. Global Antisense Oligonucleotide Therapies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antisense Oligonucleotide Therapies Revenue Share by Company (2021-2026) Table 7. Global Antisense Oligonucleotide Therapies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antisense Oligonucleotide Therapies Key Company Manufacturing Base & Headquarters Table 9. Global Antisense Oligonucleotide Therapies Company, Product Type & Application Table 10. Global Antisense Oligonucleotide Therapies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antisense Oligonucleotide Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Without GalNAc-conjugated Table 15. Significant Companies of With GalNAc-conjugated Table 16. Global Antisense Oligonucleotide Therapies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Antisense Oligonucleotide Therapies Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Antisense Oligonucleotide Therapies Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Antisense Oligonucleotide Therapies Sales Value Share by Type (2021-2026) Table 20. Global Antisense Oligonucleotide Therapies Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancer Table 22. Significant Companies of Cardiovascular Diseases Table 23. Significant Companies of Genetic Disease Table 24. Significant Companies of Other Table 25. Global Antisense Oligonucleotide Therapies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antisense Oligonucleotide Therapies Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Antisense Oligonucleotide Therapies Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Antisense Oligonucleotide Therapies Sales Value Share by Application (2021-2026) Table 29. Global Antisense Oligonucleotide Therapies Sales Value Share by Application (2027-2032) Table 30. Global Antisense Oligonucleotide Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antisense Oligonucleotide Therapies Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Antisense Oligonucleotide Therapies Sales Value Share by Region (2021-2026) Table 33. Global Antisense Oligonucleotide Therapies Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Antisense Oligonucleotide Therapies Sales Value Share by Region (2027-2032) Table 35. Global Antisense Oligonucleotide Therapies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antisense Oligonucleotide Therapies Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Antisense Oligonucleotide Therapies Sales Value Market Share by Country (2021-2026) Table 38. Global Antisense Oligonucleotide Therapies Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Antisense Oligonucleotide Therapies Sales Value Market Share by Country (2027-2032) Table 40. Sarepta Therapeutics Company Information Table 41. Sarepta Therapeutics Business Overview Table 42. Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio Table 44. Sarepta Therapeutics Recent Development Table 45. Nippon Shinyaku Company Information Table 46. Nippon Shinyaku Business Overview Table 47. Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio Table 49. Nippon Shinyaku Recent Development Table 50. Ionis Pharmaceuticals Company Information Table 51. Ionis Pharmaceuticals Business Overview Table 52. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio Table 54. Ionis Pharmaceuticals Recent Development Table 55. Research Programs/Design for This Report Table 56. Authors List of This Report Table 57. Secondary Sources Table 58. Primary Sources List of Figures Figure 1. Antisense Oligonucleotide Therapies Product Image Figure 2. Global Antisense Oligonucleotide Therapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Antisense Oligonucleotide Therapies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Without GalNAc-conjugated Image Figure 8. With GalNAc-conjugated Image Figure 9. Global Antisense Oligonucleotide Therapies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Antisense Oligonucleotide Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Antisense Oligonucleotide Therapies Sales Value Share by Type (2021-2032) Figure 12. Cancer Image Figure 13. Cardiovascular Diseases Image Figure 14. Genetic Disease Image Figure 15. Other Image Figure 16. Global Antisense Oligonucleotide Therapies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antisense Oligonucleotide Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antisense Oligonucleotide Therapies Sales Value Share by Application (2021-2032) Figure 19. Global Antisense Oligonucleotide Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Antisense Oligonucleotide Therapies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Antisense Oligonucleotide Therapies Sales Value (2021-2032) & (US$ Million) Figure 22. North America Antisense Oligonucleotide Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Antisense Oligonucleotide Therapies Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Antisense Oligonucleotide Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Antisense Oligonucleotide Therapies Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Antisense Oligonucleotide Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Antisense Oligonucleotide Therapies Sales Value (2021-2032) & (US$ Million) Figure 28. South America Antisense Oligonucleotide Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Antisense Oligonucleotide Therapies Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Antisense Oligonucleotide Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Without GalNAc-conjugated
  • With GalNAc-conjugated
Applications
  • Cancer
  • Cardiovascular Diseases
  • Genetic Disease
  • Other
Companies covered
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • Ionis Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antisense Oligonucleotide Therapies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antisense Oligonucleotide Therapies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antisense Oligonucleotide Therapies Market Dynamics
  1. 2.1 Antisense Oligonucleotide Therapies Industry Trends
  2. 2.2 Antisense Oligonucleotide Therapies Industry Drivers
  3. 2.3 Antisense Oligonucleotide Therapies Industry Opportunities and Challenges
  4. 2.4 Antisense Oligonucleotide Therapies Industry Restraints
3 Antisense Oligonucleotide Therapies Market by Company
  1. 3.1 Global Antisense Oligonucleotide Therapies Company Revenue Ranking in 2025
  2. 3.2 Global Antisense Oligonucleotide Therapies Revenue by Company (2021-2026)
  3. 3.3 Global Antisense Oligonucleotide Therapies Company Ranking (2024-2026)
  4. 3.4 Global Antisense Oligonucleotide Therapies Company Manufacturing Base and Headquarters
  5. 3.5 Global Antisense Oligonucleotide Therapies Company Product Type and Application
  6. 3.6 Global Antisense Oligonucleotide Therapies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antisense Oligonucleotide Therapies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antisense Oligonucleotide Therapies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antisense Oligonucleotide Therapies Market by Type
  1. 4.1 Antisense Oligonucleotide Therapies Type Introduction
  2. 4.1.1 Without GalNAc-conjugated
  3. 4.1.2 With GalNAc-conjugated
  4. 4.2 Global Antisense Oligonucleotide Therapies Sales Value by Type
  5. 4.2.1 Global Antisense Oligonucleotide Therapies Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antisense Oligonucleotide Therapies Sales Value by Type (2021-2032)
  7. 4.2.3 Global Antisense Oligonucleotide Therapies Sales Value Share by Type (2021-2032)
5 Antisense Oligonucleotide Therapies Market by Application
  1. 5.1 Antisense Oligonucleotide Therapies Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Cardiovascular Diseases
  4. 5.1.3 Genetic Disease
  5. 5.1.4 Other
  6. 5.2 Global Antisense Oligonucleotide Therapies Sales Value by Application
  7. 5.2.1 Global Antisense Oligonucleotide Therapies Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antisense Oligonucleotide Therapies Sales Value by Application (2021-2032)
  9. 5.2.3 Global Antisense Oligonucleotide Therapies Sales Value Share by Application (2021-2032)
6 Antisense Oligonucleotide Therapies Regional Value Analysis
  1. 6.1 Global Antisense Oligonucleotide Therapies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antisense Oligonucleotide Therapies Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antisense Oligonucleotide Therapies Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antisense Oligonucleotide Therapies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antisense Oligonucleotide Therapies Sales Value (2021-2032)
  7. 6.3.2 North America Antisense Oligonucleotide Therapies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antisense Oligonucleotide Therapies Sales Value (2021-2032)
  10. 6.4.2 Europe Antisense Oligonucleotide Therapies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antisense Oligonucleotide Therapies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antisense Oligonucleotide Therapies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antisense Oligonucleotide Therapies Sales Value (2021-2032)
  16. 6.6.2 South America Antisense Oligonucleotide Therapies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antisense Oligonucleotide Therapies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antisense Oligonucleotide Therapies Sales Value Share by Country, 2025 VS 2032
7 Antisense Oligonucleotide Therapies Country-level Value Analysis
  1. 7.1 Global Antisense Oligonucleotide Therapies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antisense Oligonucleotide Therapies Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antisense Oligonucleotide Therapies Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antisense Oligonucleotide Therapies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antisense Oligonucleotide Therapies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antisense Oligonucleotide Therapies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antisense Oligonucleotide Therapies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sarepta Therapeutics
  2. 8.1.1 Sarepta Therapeutics Company Information
  3. 8.1.2 Sarepta Therapeutics Business Overview
  4. 8.1.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio
  6. 8.1.5 Sarepta Therapeutics Recent Developments
  7. 8.2 Nippon Shinyaku
  8. 8.2.1 Nippon Shinyaku Company Information
  9. 8.2.2 Nippon Shinyaku Business Overview
  10. 8.2.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio
  12. 8.2.5 Nippon Shinyaku Recent Developments
  13. 8.3 Ionis Pharmaceuticals
  14. 8.3.1 Ionis Pharmaceuticals Company Information
  15. 8.3.2 Ionis Pharmaceuticals Business Overview
  16. 8.3.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio
  18. 8.3.5 Ionis Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst